Anticancer research最新文献

{"title":"Urethral Visualization Using Near-infrared Light Observation During Transanal/Perineal Total Mesorectal Excision.","authors":"Keisuke Goto, Shunjin Ryu, Yuta Imaizumi, Sotaro Iwauchi, Takehiro Kobayashi, Ryusuke Ito, Yukio Nakabayashi","doi":"10.21873/anticanres.17511","DOIUrl":"https://doi.org/10.21873/anticanres.17511","url":null,"abstract":"<p><strong>Background/aim: </strong>Transanal total mesorectal excision is a useful technique while performing lower rectal cancer and deep pelvic surgery. However, it is a relatively difficult procedure, and unique complications such as urethral injury have been reported. Although there have been a few reports on urethral visualization, we investigated whether it is possible to visualize the urethra using a fluorescent urethral catheter.</p><p><strong>Patients and methods: </strong>We retrospectively examined the background and short-term surgical outcomes in 17 patients who, between April 2022 and December 2023, underwent transanal total mesorectal excision and transperineal total mesorectal excision with fluorescent ureteral catheters in place due to high risk of urethral injury.</p><p><strong>Results: </strong>The urethra was recognized in one out of 11 patients (9.1%) in laparoscopic abdominoperineal resection and all three patients (100%) in laparoscopic total pelvic extenteration. No urethral injury was observed.</p><p><strong>Conclusion: </strong>Visualization of the urethra by inserting a fluorescent ureteral catheter may prevent urethral injury in patients undergoing transanal/transperineal total mesorectal excision who are at high risk of urethral injury.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1241-1249"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of Residual Lymph Node Metastasis in Predicting Recurrence After Preoperative Chemotherapy and Surgery for Gastric Cancer.","authors":"Keisuke Komori, Takanobu Yamada, Shuji Ando, Shinsuke Nagasawa, Kyohei Kanematsu, Junya Morita, Mie Tanabe, Yuta Nakayama, Yasushi Rino, Aya Saito, Takashi Ogata, Takashi Oshima","doi":"10.21873/anticanres.17507","DOIUrl":"https://doi.org/10.21873/anticanres.17507","url":null,"abstract":"<p><strong>Background/aim: </strong>Neoadjuvant chemotherapy is gaining recognition for its potential to improve survival outcomes, with combined neoadjuvant and adjuvant therapies under investigation. However, the prognostic significance of post-chemotherapy pathological staging (ypStage) on recurrence-free survival (RFS) remains unclear. This study aimed to evaluate the utility of ypStage, ypT, ypN classification, and histological response rate in predicting recurrence after gastrectomy.</p><p><strong>Patients and methods: </strong>This retrospective study included 125 patients who underwent radical gastrectomy after preoperative chemotherapy at the Kanagawa Cancer Center between January 2007 and November 2019. RFS was analyzed based on ypStage, ypT, ypN classification, and histological response rate, with prognostic factors also assessed.</p><p><strong>Results: </strong>The 5-year RFS rates were 81.6% for ypStage I, 49.0% for ypStage II, and 42.9% for ypStage III. Significant differences were observed between ypStage I and ypStage II (<i>p</i>=0.025) but not between ypStage II and ypStage III (<i>p</i> =0.633). In ypStage II/III cases, the 5-year RFS rate was significantly higher for ypN0/1/2 (55.4%) compared to ypN3 (21.5%) (<i>p</i>=0.003). ypN was selected as an independent predictor for relapse in multivariate analysis.</p><p><strong>Conclusion: </strong>ypStage effectively predicts recurrence in ypStage I cases after preoperative chemotherapy and surgery for gastric cancer. However, prognosis in patients with ypStage II/III is better stratified using the ypN classification, particularly ypN3.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1205-1214"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryptic Rearrangement of the <i>KMT2A</i> Gene in a B-cell Acute Lymphoblastic Leukemia.","authors":"Marta Brunetti, Kristin Andersen, Signe Spetalen, Geir E Tjønnfjord, Sverre Heim, Francesca Micci","doi":"10.21873/anticanres.17479","DOIUrl":"https://doi.org/10.21873/anticanres.17479","url":null,"abstract":"<p><strong>Background/aim: </strong>A 30-year-old female diagnosed with B cell acute lymphoblastic leukemia (B-ALL) had a normal karyotype at diagnosis.</p><p><strong>Case report: </strong>The case was investigated further by fluorescence <i>in situ</i> hybridization (FISH), array comparative genomic hybridization (aCGH), and reverse-transcription polymerase chain reaction (RT-PCR) followed by Cycle sequencing. The diagnostic karyotype was normal (46,XX), but FISH studies on tumor cells using a <i>KMT2A</i> break-apart probes showed that the proximal part of <i>KMT2A</i> was inserted into an apparently normal chromosome 4 with concomitant loss of the distal part of the probe. aCGH identified losses within 11q23.3 and 4q21.3q22.1 with the breakpoints mapping inside the <i>KMT2A</i> and <i>AFF1</i> loci. The presence of the putative <i>KMT2A::AFF1</i> fusion gene was confirmed by FISH analysis and RT-PCR/Cycle sequencing; an in-frame fusion was detected between <i>KMT2A</i> (exon 9) and <i>AFF1</i> (exon 6). The patient underwent allogenic stem cell transplantation and reached complete remission.</p><p><strong>Conclusion: </strong>This case highlights the need to supplement banding cytogenetics with appropriate molecular (cyto)genetic techniques whenever the karyotype does not reveal characteristic aberrations. Although <i>KMT2A</i> rearrangements in both lymphoblastic and myeloid acute leukemias usually arise through karyotypically visible chromosomal recombinations, this is not always the case.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"921-928"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results.","authors":"Junji Kawada, Daisuke Sakai, Yutaka Kimura, Motohiro Hirao, Kazuhiro Nishikawa, Naotoshi Sugimoto, Yoshio Oka, Shunji Endo, Yutaka Isozaki, Jin Matsuyama, Ryohei Kawabata, Tomono Kawase, Kazumasa Fujitani, Yukinori Kurokawa, Hisato Kawakami, Toshio Shimokawa, Taroh Satoh","doi":"10.21873/anticanres.17495","DOIUrl":"https://doi.org/10.21873/anticanres.17495","url":null,"abstract":"<p><strong>Background/aim: </strong>Irinotecan is a key drug for patients with advanced gastric cancer. We assessed the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in patients with advanced human epidermal growth factor receptor type 2 (HER2)-positive chemotherapy-refractory gastric cancer.</p><p><strong>Patients and methods: </strong>Eligibility criteria included unresectable or recurrent HER2-positive gastric cancer patients who were refractory to at least one regimen of chemotherapy. Irinotecan was administered at a dose of 150 mg/m² every 2 weeks, and trastuzumab at a dose of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks. The primary endpoint was the disease control rate (DCR). The secondary endpoints were adverse events (AEs), overall response rate (ORR), time-to-treatment failure (TTF), progression-free survival (PFS), and overall survival (OS).</p><p><strong>Results: </strong>Thirty patients were enrolled, of whom 18 previously received a single chemotherapy regimen whereas 12 received two or more regimens. As one patient withdrew before the study treatment, 29 patients were assessable for efficacy and safety. The DCR was 65.5%, and the ORR was 20.7%. The median PFS and OS were 3.7 and 7.5 months, respectively. The major grade 3/4 AEs were neutropenia (24%), anemia (24%), leukopenia (21%), anorexia (11%), fatigue (14%), hypoalbuminemia (24%), and hypokalemia (14%). One treatment-related death occurred.</p><p><strong>Conclusion: </strong>These findings indicate that irinotecan plus trastuzumab is feasible with modest potential efficacy against chemotherapy-refractory advanced HER2-positive gastric cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1077-1085"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highly Synergistic Eradication of 143B Osteosarcoma Cells <i>In Vitro</i> by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, Respectively.","authors":"Sei Morinaga, Qinghong Han, Kohei Mizuta, Byung Mo Kang, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman","doi":"10.21873/anticanres.17481","DOIUrl":"https://doi.org/10.21873/anticanres.17481","url":null,"abstract":"<p><strong>Background/aim: </strong>Drug-resistant osteosarcoma is a highly aggressive malignancy with limited therapeutic options. Recombinant methioninase (rMETase) targets the methionine addiction of cancer and acts synergistically with many cancer-chemotherapy agents. The present study investigated the synergistic efficacy of the combination of rMETase, chloroquine (CQ) which targets autophagy, and rapamycin (RAPA) which targets mTOR, on human 143B osteosarcoma cells <i>in vitro</i>.</p><p><strong>Materials and methods: </strong>143B human osteosarcoma cells. 143B cells were treated under eight conditions at the IC₃₀ of each agent: untreated control; rMETase alone (0.31 U/ml); CQ alone (61.9 μM); RAPA alone (30.9 μM); rMETase (0.31 U/ml) + CQ (61.9 μM); rMETase (0.31 U/ml) + RAPA (30.9 μM); CQ (61.9 μM) + RAPA (30.9 μM); and rMETase (0.31 U/ml) + CQ (61.9 μM) + RAPA (30.9 μM). Cell viability was measured with the WST-8 reagent.</p><p><strong>Results: </strong>Each of the single-agents, rMETase, CQ, and RAPA demonstrated moderate cytotoxicity when administered alone to 143B cells. The dual combination of CQ plus RAPA had the highest efficacy compared to single agents and compared to rMETase plus CQ and rMETase plus RAPA, which had moderate efficacy. In contrast, the triple combination of rMETase, CQ, plus RAPA exhibited strong synergistic efficacy, eradicating 143B cells.</p><p><strong>Conclusion: </strong>The triple combination of rMETase, CQ, and RAPA demonstrated strong synergy and effectively eradicated 143B osteosarcoma cells. Therefore, the triple treatment with rMETase, CQ, and RAPA has potential as a novel, effective therapeutic approach for osteosarcoma.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"935-941"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA XIST Promotes Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma Cells <i>via</i> Regulation of miR-186-5p/ZEB1.","authors":"Yunyun Ma, Lili Qian, Dechao Wang, Changyan Chen","doi":"10.21873/anticanres.17477","DOIUrl":"https://doi.org/10.21873/anticanres.17477","url":null,"abstract":"<p><strong>Background/aim: </strong>Accumulating evidence has indicated that long non-coding RNAs (lncRNAs) are crucial molecules for tumor progression in various human cancers. However, the function of lncRNA X-inactive specific transcript (XIST) in esophageal squamous cell carcinoma (ESCC) remains to be determined. The current study aimed to explore the function and molecular mechanism of lncRNA XIST in ESCC progression.</p><p><strong>Materials and methods: </strong>The expression level of lncRNA XIST in ESCC cell lines was measured by qRT-PCR. The effects of lncRNA XIST on cell proliferation, migration, and invasion on ESCC were detected by CCK-8, transwell, and scratch assays. The expression levels of proteins were determined by western blot and luciferase reporter assays were used to identify specific target relationships.</p><p><strong>Results: </strong>LncRNA XIST was overexpressed in ESCC cell lines when compared to normal cell lines. The inhibitor of lncRNA XIST markedly inhibited ESCC cell proliferation, migration, and invasion. Furthermore, miR-186-5p was down-regulated in ESCC cells. LncRNA XIST could sponge miR-186-5p and knockdown of lncRNA XIST could increase the expression of miR-186-5p. We also confirmed Zinc finger E-box binding homeobox 1 (ZEB1) as the target for miR-186-5p, while overexpression of ZEB1 reversed the effects of miR-186-5p inhibition on the malignant behavior of EC9706 and KYSE30 cells.</p><p><strong>Conclusion: </strong>Our data revealed that lncRNA XIST promotes ESCC metastasis by regulating the miR-186-5p/ZEB1 axis. This study may provide a theoretical basis for the molecular mechanisms involved in esophageal cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"897-908"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Keratin-10 in Tumor Progression and Radioresistance of Laryngeal Cancer Cells.","authors":"Eun Kyung Jung, Sun-Ae Kim, S M Abdus Salam, Kyung-Hwa Lee, Tae Mi Yoon","doi":"10.21873/anticanres.17490","DOIUrl":"https://doi.org/10.21873/anticanres.17490","url":null,"abstract":"<p><strong>Background/aim: </strong>Advanced laryngeal cancer is challenging to treat, and overall survival rates are low. The high rate of disease recurrence contributes significantly to poor outcomes. This study investigated the role of keratin-10 (KRT10), identified through RNA sequencing as a potential target molecule in laryngeal cancer, in the tumor progression and radioresistance of laryngeal cancer cells.</p><p><strong>Materials and methods: </strong>RNA sequencing data from 32 formalin-fixed, paraffin-embedded samples of stage III or IV advanced laryngeal cancer obtained through biopsy were analyzed and a positive association between KRT10 expression and tumor recurrence was observed. We performed <i>in vitro</i> experiments using human laryngeal cancer cell lines (PCl1 and SNU1066) with/without <i>KRT10</i> knockdown. Reverse-transcription polymerase chain reaction and western blot analysis were performed. Cell irradiation was performed to analyze differences in radiosensitivity and cell invasion, migration, and apoptosis were analyzed.</p><p><strong>Results: </strong>Knockdown of <i>KRT10</i> expression in laryngeal cancer cell lines with small interfering RNAs significantly reduced cell invasion and migration, but increased apoptosis. <i>KRT10</i> knockdown also enhanced radiosensitivity, resulting in a higher rate of apoptosis in response to radiation therapy.</p><p><strong>Conclusion: </strong>These findings suggest that KRT10 plays a crucial role in tumor progression and radioresistance of laryngeal cancer and that KRT10 is a potential therapeutic target. Further studies are needed to validate these results, but to our knowledge, this is the first report of evidence identifying KRT10 as a potential target molecule in laryngeal cancer management.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1035-1045"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailoring Neoadjuvant Therapy for Rectal Cancer: A Single-center Study of Local Recurrence Patterns.","authors":"Ryohei Shoji, Fuminori Teraishi, Yoshitaka Kondo, Yusuke Yoshida, Nobuhiko Kanaya, Yuki Matsumi, Kunitoshi Shigeyasu, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"10.21873/anticanres.17513","DOIUrl":"https://doi.org/10.21873/anticanres.17513","url":null,"abstract":"<p><strong>Background/aim: </strong>Postoperative local recurrence remains an important issue in rectal cancer, and the optimal treatment strategy, surgical approach, and prognosis after treatment are yet to be addressed.</p><p><strong>Patients and methods: </strong>We reviewed 21 patients who underwent surgical resection at our department for postoperative pelvic local recurrence of rectal cancer between January 2013 and December 2022, and performed a retrospective analysis of outcomes in terms of preoperative treatment and surgical approach.</p><p><strong>Results: </strong>Of the 21 patients, four (19%) were treated with upfront surgery (Upfront surgery group), 13 (62%) with chemotherapy (Chemotherapy group), and four (19%) with neoadjuvant chemoradiotherapy (NACRT; NACRT group). The surgical approach was open laparotomy (Open group) in 10 (47.6%) patients and minimally invasive surgery (MIS, MIS group) in 11 (52.4%). Seventeen (81.0%) had a negative resection margin (RM). Overall median postoperative survival was 71 months and median relapse-free survival was 6.2 months. The most common form of recurrence was pelvic local re-recurrence in seven patients (33.3%). By preoperative treatment type, the RM securement rate was higher in the Chemotherapy and NACRT groups than in the Upfront surgery group, and the postoperative recurrence rate was lowest in the NACRT group. By surgical approach, intraoperative blood loss and incidence of Clavien-Dindo Grade 3 or higher postoperative adverse events were both significantly lower in the MIS group than in the Open group.</p><p><strong>Conclusion: </strong>Surgical intervention for postoperative recurrence of rectal cancer results in good survival, but short relapse-free survival. NACRT can deter local re-recurrence after resection, and MIS may contribute to reducing complications.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1261-1271"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies.","authors":"Junichiro Hirata, Takuto Hara, Naoe Jimbo, Hideto Ueki, Yasuyoshi Okamura, Yukari Bando, Kotaro Suzuki, Tomoaki Terakawa, Jun Teishima, Koji Chiba, Hideaki Miyake","doi":"10.21873/anticanres.17501","DOIUrl":"https://doi.org/10.21873/anticanres.17501","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to investigate the genomic features of small cell neuroendocrine prostate cancer (SCPC) in Japanese patients, assess their relationships with platinum-based chemotherapy efficacy, and evaluate the potential treatment eligibility for therapies using cancer genomic profiling.</p><p><strong>Patients and methods: </strong>This retrospective study included 21 patients diagnosed with SCPC between 2018 and 2022. An expert pathologist reviewed the biopsy specimens according to the World Health Organization prostate cancer classification. Biopsy samples from primary or metastatic lesions were analyzed using FoundationOne^® CDx to identify genomic mutations, focusing on DNA damage repair (DDR) mutations and other clinically relevant alterations. Platinum-based chemotherapy efficacy was assessed using progression-free survival (PFS) and overall survival (OS) outcomes.</p><p><strong>Results: </strong>DDR mutations were detected in eight (38.1%) patients, and <i>BRCA</i> mutations were present in three (14.3%) cases. <i>TP53</i> and <i>RB1</i> mutations were identified in 15 (71.4%) and 12 (57.1%) cases, respectively. Three (14.8%) patients were identified with microsatellite instability-high or tumor mutational burden-high, making them eligible for immune checkpoint inhibitor treatment. PFS/OS rates suggested that the presence of these mutations did not significantly impact platinum-based chemotherapy efficacy. Six (28.6%) patients were eligible for treatments approved for prostate cancer in Japan as of 2024.</p><p><strong>Conclusion: </strong>This study is the first to reveal the SCPC genomic landscape in Japanese patients. Although genomic mutations, including DDR mutations, were not predictive of platinum-based chemotherapy efficacy, active genomic testing may improve access to targeted therapies for this challenging malignancy, especially where treatment options are limited.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1137-1147"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glymphatic Insights in Glioblastoma.","authors":"Ashwin Kumaria, Keyoumars Ashkan","doi":"10.21873/anticanres.17517","DOIUrl":"https://doi.org/10.21873/anticanres.17517","url":null,"abstract":"","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1301-1303"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}